Loading
Gastrointestinal oncologist who led FIRE-3, a key trial of cetuximab versus bevacizumab in colorectal cancer.
Volker Heinemann is Director of the Comprehensive Cancer Center Munich at LMU Klinikum München and Professor of Medical Oncology. His specialisms are colorectal cancer, pancreatic ductal adenocarcinoma and anti-EGFR therapy. He led FIRE-3, the Lancet Oncology trial of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer, a key comparison that shaped the use of anti-EGFR therapy according to tumour sidedness. His record links him to the CRYSTAL and FIRE-3 trials, and his publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) | Lancet Oncology | 2014 |
It showed the sidedness effect is not an artefact of pooling and survives adjustment for BRAF, which is what made guideline committees act on it.
The analysis that put 'left-sided, RAS and BRAF wild-type' into every guideline as the anti-EGFR population, and made an anatomical fact into a treatment-selection biomarker.
Together with PARADIGM it makes the EGFR antibody the preferred first partner for chemotherapy in left-sided RAS wild-type disease; the survival gain without a progression-free survival gain remains one of the field's unexplained results.
Shares FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3), Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Cetuximab, Bevacizumab.
Shares Cetuximab, Bevacizumab, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares CRYSTAL & FIRE-3, Cetuximab, Colorectal cancer.
Shares CRYSTAL & FIRE-3, Cetuximab, Colorectal cancer.
Shares Cetuximab, Bevacizumab, Colorectal cancer.
Shares Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials, CRYSTAL & FIRE-3, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Metastatic pancreatic ductal adenocarcinoma.
Shares Cetuximab, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares CRYSTAL & FIRE-3, Cetuximab, Bevacizumab, Colorectal cancer.